Disease Intelligence Center · Pandemic II
Type 2 Diabetes
Beta-cell stress is modeled as the end point of several drivers at once: glycemic load and nutrient quality, oxidative and mitochondrial stress, hormonal signaling, low-grade inflammation and selected exposures.
Domain weighting
Organizational emphasisiWeightings describe where this framework directs attention for this condition. They are not a measure of how much any factor caused an individual case.
Root-cause chain
Each link carries its own evidence grade- Sustained hyperglycemia and glycemic variability→Beta-cell oxidative stressOA
Glucotoxicity and lipotoxicity raise mitochondrial ROS and impair insulin secretion; reproduced across human and preclinical evidence.
Relationship: Established causal
- Low-grade systemic inflammation→Peripheral insulin resistanceIA
Cytokine-mediated interference with insulin receptor signaling in muscle and liver.
Relationship: Established causal
- Magnesium or chromium insufficiency→Reduced insulin sensitivityNC
Cofactor roles in glucose handling; intervention data are mixed and deficiency-dependent.
Relationship: Observational association
- Persistent organic pollutant exposure→Impaired glucose toleranceTC
Several cohorts report associations with incident diabetes; confounding and reverse causation are not excluded.
Relationship: Observational association
iDetection of an exposure does not establish that it caused a disease. This platform separates exposure, association, plausible mechanism, clinical evidence and demonstrated causation.
Fifth Estate considerations
Microbial ecologyGut barrier function and bile-acid signaling are tracked as modifiers of glycemic control; detection of an organism is not treated as infection.
Go deeper
TOBIN Intelligence LibraryThe full evidence review for Type 2 Diabetes: each mechanism by domain, what is established versus uncertain, related pandemics, relevant labs and how they move your scores.
Open the Type 2 Diabetes evidence reviewProtocol Fusion Engine
Six lanes · evidence grade and regulatory status on every entryConventional
Guideline-standard glucose lowering with long-term safety data.
Caution: Avoid in advanced renal impairment; monitor B12, which metformin can deplete.
Functional
Improves time-in-range and dietary adherence.
Caution: Avoid over-interpretation of single excursions.
Integrative
Lowers HbA1c independently of weight change.
Caution: Adjust insulin or sulfonylurea dosing to avoid hypoglycemia.
Orthomolecular
Addresses a documented drug–nutrient depletion.
Caution: Confirm deficiency; investigate macrocytosis and neuropathy properly.
Traditional
Small trials suggest modest glycemic effects; not a substitute for therapy.
Caution: Hepatotoxicity concerns with high-coumarin cassia cinnamon; interaction risk with anticoagulants.
Energy / Physical
Energy medicine on Tayapulse →Preliminary and inconsistent symptom data only.
Caution: Not a glucose-lowering therapy; avoid with implanted electronic devices.
iLanes are presented side by side so the difference in evidence strength is visible. Nothing here is a prescription, and interactions must be reviewed with your clinician and pharmacist.
iEnergy and physical modalities in this lane are explored further with Tayapulse. Evidence grade and regulatory status still apply: these are adjuncts used only where indicated, never cures or replacements for guideline care.
Diagnostics to consider
- · HbA1c, fasting glucose, OGTT where indicated
- · Fasting insulin and C-peptide
- · ApoB, lipids, urine albumin-creatinine ratio
- · Retinal and foot examination per guideline
Monitoring
- · HbA1c every 90 days until target
- · Renal function and albuminuria annually
- · Hypoglycemia review at each medication change
Prevention emphasis
- · Carbohydrate quality and fiber targets
- · Post-meal activity
- · Weight reduction where indicated
- · Annual screening in high-risk patients